Processing your request

please wait...

Case Page


Case Status:    ONGOING    
On or around 03/10/2020 (Date of last review)

Filing Date: December 10, 2019

According to the Complaint, Adamas Pharmaceuticals, Inc. is a commercial stage pharmaceutical company that specializes in developing drug treatment therapies for chronic neurologic disorders.

The Complaint alleges that throughout the Class Period, Adamas' public statements were false and materially misleading.

On March 3, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: ADMS
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: N.D. California
DOCKET #: 19-CV-08051
JUDGE: Hon. Jeffrey S. White
DATE FILED: 12/10/2019
CLASS PERIOD END: 09/30/2019
  1. Franklin D. Azar & Associates, P.C.
  2. The Schall Law Firm
  3. Thornton Law Firm, LLP (Beverly Hills)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available